<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281905</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454575</org_study_id>
    <secondary_id>CCLG-CNS-9204</secondary_id>
    <secondary_id>EU-20574</secondary_id>
    <secondary_id>CCLG-CNS-1992-04</secondary_id>
    <nct_id>NCT00281905</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors</brief_title>
  <official_title>Management of Children Aged Less Than 3 Years With Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy&#xD;
      x-rays to kill tumor cells. Giving radiation therapy after chemotherapy may kill any&#xD;
      remaining tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with or without radiation therapy works in treating children with brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in children under 36 months of age with primary brain or&#xD;
           brain stem tumors treated with vincristine, methotrexate, carboplatin, cyclophosphamide,&#xD;
           and cisplatin with or without radiotherapy.&#xD;
&#xD;
        -  Determine the event-free survival and overall survival in children treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the pattern of local recurrence or occurrence of CNS metastases in children&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the quality of life in children treated with this regimen.&#xD;
&#xD;
        -  Determine the tolerability and long-term toxicity of this regimen in these children.&#xD;
&#xD;
        -  Determine the proportion of children who require radiotherapy after treatment with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the prognosis of children who receive both chemotherapy and radiotherapy.&#xD;
&#xD;
        -  Determine the nature and behavior of brain tumors in very young children.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Chemotherapy: Patients receive vincristine IV on days 0, 14, and 28; carboplatin IV over&#xD;
           4 hours on day 0; methotrexate IV continuously over 24 hours on day 14; cyclophosphamide&#xD;
           IV over 4 hours on day 28; and cisplatin IV continuously over 48 hours on days 42 and&#xD;
           43. Courses repeat every 56 days (8 weeks) for up to 12 months. Patients who achieve a&#xD;
           complete response proceed to observation, as do those achieving a partial response with&#xD;
           no tumor present on biopsy. Patients with biopsy proven residual tumors after 12 months&#xD;
           of chemotherapy or recurrent tumors that don't have the potential to spread through the&#xD;
           cerebrospinal fluid (CSF) proceed to local radiotherapy. Patients with unresponsive&#xD;
           disease or progressive disease that has the potential to spread through the CSF proceed&#xD;
           to craniospinal radiotherapy.&#xD;
&#xD;
        -  Local radiotherapy: Patients undergo local radiotherapy 5 days a week for 5-5Â½ weeks.&#xD;
&#xD;
        -  Craniospinal radiotherapy: Patients undergo craniospinal radiotherapy 5 days a week for&#xD;
           4 weeks.&#xD;
&#xD;
      Quality of life is assessed periodically.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1992</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Local recurrence or occurrence of CNS metastases</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerance</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients requiring radiotherapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognosis of children who receive both chemotherapy and radiotherapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature and behavior of brain tumors</measure>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Brain stem tumor (histological confirmation not required)&#xD;
&#xD;
               -  Histologically confirmed primary intracranial brain tumor of 1 of the following&#xD;
                  histologies:&#xD;
&#xD;
                    -  Anaplastic (malignant) astrocytoma&#xD;
&#xD;
                    -  Glioblastoma&#xD;
&#xD;
                    -  Anaplastic (malignant) oligodendroglioma&#xD;
&#xD;
                    -  Ependymoma&#xD;
&#xD;
                    -  Anaplastic (malignant) ependymoma&#xD;
&#xD;
                    -  Anaplastic (malignant) oligoastrocytoma&#xD;
&#xD;
                    -  Choroid plexus carcinoma&#xD;
&#xD;
                    -  Astroblastoma&#xD;
&#xD;
                    -  Polar spongioblastoma&#xD;
&#xD;
                    -  Gliomatosis cerebri&#xD;
&#xD;
                    -  Anaplastic (malignant) ganglioglioma&#xD;
&#xD;
                    -  Pineoblastoma&#xD;
&#xD;
                    -  Mixed pineocytoma or pineoblastoma&#xD;
&#xD;
                    -  Medulloepithelioma&#xD;
&#xD;
                    -  Neuroblastoma&#xD;
&#xD;
                    -  Ependymoblastoma&#xD;
&#xD;
                    -  Primitive neuroectodermal tumors (PNETs), including medulloblastoma or&#xD;
                       cerebral or spinal PNETs&#xD;
&#xD;
          -  Has undergone surgery or biopsy of the tumor within the past 2-4 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No concurrent unrelated disease, including hematological or renal disease, that would&#xD;
             preclude study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  Prior steroids allowed&#xD;
&#xD;
          -  No concurrent steroids as anti-emetics&#xD;
&#xD;
               -  Concurrent steroids allowed for control of tumor-related symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Grundy, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Queen's Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

